Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs

• US 6,310,040 B1
• Filed: 10/15/1992
• Issued: 10/30/2001
• Est. Priority Date: 11/08/1991
• Status: Expired due to Term

• Current Assignee: Cephalon Incorporated (Teva Pharmaceutical Industries Limited)
• Original Assignee: Cephalon Incorporated (Teva Pharmaceutical Industries Limited)
• Inventors: Bozyczko-Coyne, Donna, Iqbal, Mohamed A., Neff, Nicola, Lewis, Michael E.
• Primary Examiner(s): EYLER, YVONNE L
• Application Number:
  US07/963,329
• Time in Patent Office: 3,302 Days
• Field of Search: 514/12, 514/3, 514/4, 514/21, 514/912, 424/570, 530/839, 530/303
• US Class Current: 514/8.3
• CPC Class Codes: A01N 57/20 containing acyclic or cycloaliphatic radicals
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: C07F 9/301 Acyclic saturated acids which can have further substituents on alkyl
• CPC Class Codes: C07F 9/3813 N-Phosphonomethylglycine; Salts or complexes thereof
• CPC Class Codes: C07K 14/65 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
• CPC Class Codes: Y10S 530/839 Nerves; brain

Abstract

Disclosed is a method for promoting retinal neuronal survival in a mammal, wherein the neuronal cells are at risk of dying. The method comprises administering to the mammal an effective dose of at least one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; or a functional derivative of IGF-II.

Claims

1. A method for promoting the survival of photoreceptors in a mammal, said photoreceptors being at risk of dying, said method comprising administering to said mammal an effective dose of Insulin-like Growth Factor-I.